Australia to begin human trials for COVID-19 vaccine made by China
Category: #headlines  By Saipriya Iyer  Date: 2020-04-29
  • share
  • Twitter
  • Facebook
  • LinkedIn
Australia to begin human trials for COVID-19 vaccine made by China

Linear Clinical Research, a research and clinical facility in Perth, Australia, has confirmed a human trial of a coronavirus vaccine that has been developed by China. Sources familiar with the matter said that research and clinical facility has already initiated the recruitment of healthy adults to participate in the trial within the coming two months.

S-Trimer vaccine, which is primarily developed by a biotechnology company called Clover Biopharmaceuticals, located in China, is believed to be one of the first COVID-19 vaccines to be under development. Linear had also made an announcement regarding the vaccine trial on the website and also called on the people who are interested in being registered with the company.

The company issued the statement that if people were feeling unhealthy and were located in Perth, WA, they could register their interest to be able to participate in the forthcoming COVID-19 vaccine study of the company.

According to a reliable source, the protein-based vaccine S-Trimer, is aimed at helping the body in producing anti-bodies to fight the virus.

Jayden Rogers, Linear’s chief executive commented that the trial was among the most vital trials across the globe and involves some extremely renowned vaccine firms. The S-Trimer vaccine had shown promising potential on the trial and has been placed at the forefront of the world’s battle with coronavirus pandemic.

The Chinese authorities had approved the human testing for two other COVID-19 vaccines recently in the month of April that were developed by the Wuhan Institute of Biological Products. This was done under the Sinovac Research and Development Co and China National Pharmaceutical Group (Sinopharm).

Apparently, Sinopharm has been able to produce more than 50,000 doses for the clinical trials. Once the production gets normalized, the output is capable of reaching about 3 million doses per batch and an annual output would be at 100 million doses.

 

Source Credit- https://www.aa.com.tr/en/asia-pacific/australia-set-for-chinese-covid-19-vaccine-human-trial-/1821328

 

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Saipriya Iyer

Saipriya Iyer    

Saipriya Iyer currently works as a content developer for GroundAlerts. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had previous experience of 3 years under her belt, she has dabbled with website ...

Read More >>

More News By Saipriya Iyer

iKure Techsoft looking to raise USD 5 million in Series A funding round
iKure Techsoft looking to raise USD 5 million in Series A funding round
By Saipriya Iyer

Ratan Tata funded iKure Techsoft, a technology-driven healthcare services startup, is reportedly planning to raise capital for expanding its presence in home grounds and beyond borders while strengthening its technology solutions. Sources with knowl...

Apple to launch self-driving cars with new battery technology in 2024
Apple to launch self-driving cars with new battery technology in 2024
By Saipriya Iyer

American multinational technology company, Apple Inc., has reportedly made advances in its self-driving car technology project and is planning on initiating the production by the year 2024. Although the tech giant has never publicly acknowledged thi...

Eurofins Technologies launches new product line for allergen detection
Eurofins Technologies launches new product line for allergen detection
By Saipriya Iyer

Leading distributor of test kits and systems for laboratory research, Eurofins Technologies, has reportedly introduced SENSIStrip Allergen, a new lateral flow device product line for detecting allergen in packaged food products. For those uninitiate...